{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:49:10Z","timestamp":1790272150563,"version":"4.1.0"},"reference-count":33,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"34","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has generally been limited to immunomodulatory agents. Other options that complement the induction regimen with favorable toxicity are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>The phase III, double-blind, placebo-controlled TOURMALINE-MM4 study randomly assigned (3:2) patients with NDMM not undergoing ASCT who achieved better than or equal to partial response after 6-12 months of standard induction therapy to receive the oral proteasome inhibitor (PI) ixazomib or placebo on days 1, 8, and 15 of 28-day cycles as maintenance for 24 months. The primary endpoint was PFS since time of randomization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Patients were randomly assigned to receive ixazomib (n = 425) or placebo (n = 281). TOURMALINE-MM4 met its primary endpoint with a 34.1% reduction in risk of progression or death with ixazomib versus placebo (median PFS since randomization, 17.4 v 9.4 months; hazard ratio [HR], 0.659; 95% CI, 0.542 to 0.801; P &lt; .001; median follow-up, 21.1 months). Ixazomib significantly benefitted patients who achieved complete or very good partial response postinduction (median PFS, 25.6 v 12.9 months; HR, 0.586; P &lt; .001). With ixazomib versus placebo, 36.6% versus 23.2% of patients had grade \u2265 3 treatment-emergent adverse events (TEAEs); 12.9% versus 8.0% discontinued treatment because of TEAEs. Common any-grade TEAEs included nausea (26.8% v 8.0%), vomiting (24.2% v 4.3%), and diarrhea (23.2% v 12.3%). There was no increase in new primary malignancies (5.2% v 6.2%); rates of on-study deaths were 2.6% versus 2.2%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Ixazomib maintenance prolongs PFS with no unexpected toxicity in patients with NDMM not undergoing ASCT. To our knowledge, this is the first PI demonstrated in a randomized clinical trial to have single-agent efficacy for maintenance and is the first oral PI option in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.20.02060","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T15:59:28Z","timestamp":1601999968000},"page":"4030-4041","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":76,"title":["Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial"],"prefix":"10.1200","volume":"38","author":[{"given":"Meletios A.","family":"Dimopoulos","sequence":"first","affiliation":[{"name":"Hematology and Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"\u0160pi\u010dka","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Melbourne, St Vincent\u2019s Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigaci\u00f3 contra la Leuc\u00e8mia Josep Carreras and Institut Catal\u00e0 d\u2019Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"H\u00e1jek","sequence":"additional","affiliation":[{"name":"Department of Hemato-oncology, University Hospital Ostrava, University of Ostrava, and Faculty of Medicine, Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Garg","sequence":"additional","affiliation":[{"name":"Hematology, Leicester Royal Infirmary\/University Hospitals of Leicester NHS Trust, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bringhen","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Citt\u00e0 della Salute e della Scienza di Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Katodritou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee-Joo","family":"Chng","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute, National University Health System, and Yong Loo Lin School of Medicine and Cancer Science Institute of Singapore, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"P\u00f4le R\u00e9gional de Canc\u00e9rologie, Department of Haematology, Centre Hospitalier Universitaire La Mil\u00e9trie-Poitiers, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"Hematology, Hospital Universitario de Salamanca, University Hospital of Salamanca, Centro de Investigaci\u00f3n del C\u00e1ncer, Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer, (Universitario de Salamanca Consejo Superior de Investigaciones Cient\u00edficas), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Morgan","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, NYU Langone Health, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Vorog","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Labotka","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingxia","family":"Wang","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the TOURMALINE-MM4 study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.2466"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.212"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2961"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.03.021"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0049"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32956-3"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30687-9"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6679"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0440"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-795047"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3546-8"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33003-4"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2307\/2530245"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0931"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1474745"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25134"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402888"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-573733"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8216"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.7618"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000560632.24271.d7"},{"key":"B35","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ejh.13231","volume":"102","author":"Dimopoulos MA","year":"2019","journal-title":"Eur J Haematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(20)30955-1"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"}],"updated-by":[{"DOI":"10.1200\/jco.22.00210","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000}}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.20.02060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:38:34Z","timestamp":1696811914000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.20.02060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":33,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2020,12,1]]}},"alternative-id":["10.1200\/JCO.20.02060"],"URL":"https:\/\/doi.org\/10.1200\/jco.20.02060","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"2020-08-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}